Natera, Inc. - NTRA STOCK NEWS

Natera, Inc. (NTRA) announced the presentation of new data on its Prospera test at the American Society of Transplant Surgeons (ASTS) 21st Annual Winter Symposium from January 14-16, 2021. The company will showcase five posters demonstrating how the Prospera test can detect kidney transplant rejection. Highlights include a study showing 56.2% of patients with delayed graft function had elevated donor-derived cfDNA levels, and a separate analysis indicating a 64.3% active rejection rate among kidney transplant recipients with positive results from the Prospera test.

Natera (NASDAQ: NTRA) announced the presentation of new findings on its Signatera test at the 2021 ASCO GI Symposium from January 15-17, 2021. This includes an oral presentation by Tenna V. Henriksen on January 16, highlighting a multi-center study of 265 colorectal cancer patients that indicates early detection of recurrence 8 months prior to traditional methods. A poster presentation will also feature a study of 122 stage II-III patients, showing a correlation between minimal residual disease (MRD) status and relapse rates.

Natera, a leader in cell-free DNA testing, will webcast a live presentation at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 12:40 p.m. PT. CEO Steve Chapman and CFO Mike Brophy will discuss the company's recent business activities and provide an overview, followed by a Q&A session. Investors can access the live presentation and archived content on investor.natera.com. Natera aims to transform disease management worldwide, focusing on women's health, oncology, and organ health.

Natera, Inc. (NASDAQ: NTRA) announced a significant win as the U.S. Patent Office upheld the validity of its U.S. Patent No. 8,682,592, denying a challenge from a multi-national sequencing company. This patent covers innovative methods for generating genetic data from limited DNA quantities, crucial in non-invasive prenatal testing and oncology. The Patent Office's decision highlights Natera's pioneering role in cfDNA testing, with only 20% of similar challenges resulting in a favorable outcome. Natera's early priority date of 2005 further solidifies its leadership in the field.

Natera, Inc. (NASDAQ: NTRA) will present new data on its personalized tumor-informed molecular residual disease (MRD) test, Signatera, at the ESMO IO Virtual Congress on December 10, 2020. The study involves 581 muscle invasive urothelial carcinoma patients from the IMvigor010 trial, assessing adjuvant treatment with atezolizumab. Interim results indicate ctDNA-positive patients showed improved overall survival of 25.8 months with treatment versus 15.8 months with observation (HR=0.59). The findings underscore Signatera's potential for patient selection in personalized cancer therapy.

Natera (NASDAQ: NTRA) announced its participation in the 2020 virtual San Antonio Breast Cancer Symposium (SABCS) from December 8-11, 2020. The company will present new data on its Signatera tumor-informed circulating tumor DNA (ctDNA) assay. Highlights include two posters: one on Signatera as a predictive biomarker in the I-SPY2 Trial and the other on comprehensive plasma-based whole exome analysis in the Beyond BRCA study. These presentations emphasize Signatera's role in monitoring treatment response and addressing drug resistance in breast cancer.

Natera, Inc. (NASDAQ: NTRA) announced that the second-largest commercial health plan in the U.S. has expanded coverage for non-invasive prenatal testing (NIPT) to all singleton pregnancies. This follows recent coverage expansions by other major health plans, resulting in over 90% of commercially-covered lives now having average-risk NIPT coverage. Natera's unique SNP-based NIPT technology aims to enhance prenatal care and reduce false negatives and positives, significantly impacting health outcomes. The company's Panorama test is a leading NIPT, backed by extensive clinical evidence.

Natera, Inc. (NASDAQ: NTRA) announced that the largest health plan in the U.S. will now cover non-invasive prenatal testing (NIPT) for all pregnancies. This decision follows a recent guideline from the American College of Obstetricians and Gynecologists (ACOG), promoting aneuploidy screening for all patients. The expanded coverage addresses previous barriers to adoption, potentially increasing the average risk NIPT market, which remains underpenetrated. Natera aims for profitability in its Women's Health business by 2021, capitalizing on this expansion and the positive health outcomes associated with NIPT.

Natera (NASDAQ: NTRA) announced a study published in Annals of Oncology demonstrating its ctDNA assay, Signatera, can effectively monitor neoadjuvant chemotherapy (NAC) responses in breast cancer patients. The study involved 291 plasma samples from 84 patients, revealing that early ctDNA clearance is significantly associated with achieving pathologic complete response (pCR), which indicates better survival outcomes. The findings suggest Signatera could improve treatment decisions and outcomes for breast cancer patients, particularly in predicting metastatic recurrence.